May 3, 2021 -- Enteris BioPharma has expanded its Boonton, NJ, manufacturing facility and launched a contract development and manufacturing organization (CDMO) business unit.
The two actions will help the firm further develop and manufacture solid oral doses for biopharmaceutics classification system (BCS) III and IV compounds, it said.
The expanded facility is 32,000 sq ft, of which 6,000 sq ft is cleanroom space and 2,500 is for containment and processing of high-potency active pharmaceutical ingredients (APIs).